The statement notes, The need for controlling the allocation of trauma centers, along with the need for an activity to designate trauma centers based on regional people need, has been recognized as an essential component of trauma system style since the 1980s. Non-etheless, few trauma systems can operationalize these concepts, particularly when faced with genuine or potential challenges that stem from powerful health care institutions or providers. At their core, trauma systems are developed to achieve care that is optimal for injured patients.Unfortunately all cancer therapies, despite their achievement, are tied to the development of medication resistance. The initiatives of several scientific groups in the last few decades have led to the identification of genes and molecular signalling mechanisms that contribute to drug resistance which includes helped us to understand the biology of malignancy and how they adjust and alter to survive and improvement. But despite this, the 5-year survival of most cancer sufferers remains poor therefore resistance to is a problem in cancer treatment. Why has the identification of the molecular mechanisms of resistance to chemotherapeutics been extremely challenging? Resistance may appear for a variety of different reasons such as poor absorption of the cytotoxic medication, rapid excretion or metabolism of the medication, poor tolerance by the individual resulting in sub-optimum dosing, the tumour microenvironment which might affect the rate of metabolism or delivery of medication and genetic and epigenetic factors which alter the cells sensitivity to apoptosis, DNA damage repair and cell routine checkpoints.